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Antiarrhythmic agents are used to suppress symptoms due
to cardiac arrhythmias and, it is hoped, to prevent sudden
death
. In fact, however, these agents may promote cardiac
arrhythmias (1-3) . Moreover, it has proved difficult to sep-
arate true proarrhythmic effects of a drug from the natural
history of the cardiac arrhythmia treated . In their report,
Velebit et al . (4) set out to define proarrhythmia largely (but
not exclusively) on the basis of changes in frequency of
premature ventricular complexes after drug therapy . This
type of analysis is complicated by the enormous spontane-
ous variation in such frequency (5), particularly over long-
term electrocardiographic monitoring (6) . In addition,
changes in premature ventricular complex density relate to
one adverse effect of antiarrhythmic therapy, namely, pos-
sible exacerbation of symptoms owing to increased fre-
quency of these complexes. Apart from the issue of fre-
quency are the electrophysiologic effects of these agents in
patients with sustained ventricular tachycardia or ventricu-
lar fibrillation . It is conceivable, for example, that a drug
may not affect or increase premature ventricular complex
density but may still prevent sudden death by exerting
use-dependent (7) blocking effects on reentrant pathways or
by raising the ventricular fibrillation threshold .
Present study . Stanton et al . (8), in this issue of the
Journal, present important and interesting data concerning
proarrhythmic effects of antiarrhythmic drugs . Their defini-
tion of proarrhythmia was eminently reasonable and based
on the development of a new spontaneous arrhythmic dis-
turbance (i .e ., nonsustained, sustained or incessant ventric-
ular tachycardia, polymorphic ventricular tachycardia or
ventricular fibrillation) consonant with initiation of a given
drug. The findings of Stanton et al . are of paramount clinical
importance in documenting the frequency of severe proar-
rhythmic effects of commonly used antiarrhythmic agents .
*First, do no harm .
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Before all of their conclusions can be accepted, several
methodologic problems bear closer scrutiny . The diagnosis
of the proarrhythmic event was made on the basis of
spontaneous arrhythmias on a telemetered unit
. The diagno-
sis of repetitive nonsustained ventricular tachycardia is
never clearly defined as a proarrhythmic event because the
comparative frequency of this arrhythmia before and after
drug administration is not given . In addition, initiation of
ventricular tachycardia that required immediate termination
might not be a true proarrhythmic effect but an example of
drug inefficacy with recurrence of ventricular tachycardia
under the influence of the negative inotropic effects of a
given drug .
Comparison with previous reports . In contrast to other
reports ( ,10), Stanton et al . (8) found no clear-cut relation
between left ventricular size or ejection fraction and proar-
rhythmic effects (an increased incidence of abnormal frac-
tional shortening was found in the proarrhythmic group) .
This was perhaps related to a bias against using several of
the more proarrhythmic agents in patients with more im-
paired left ventricular function. The absence of reported
polymorphic ventricular tachycardia for patients treated
with type IA drugs is somewhat surprising . Prior prospective
reports (11) have shown that the incidence of proarrhythmia
for this patient group may be as high as 5% . Were type IA
drugs terminated during monitoring if marked prolongation
of the QT interval was observed? The incidence of acute
proarrhythmic effects after amiodarone appears somewhat
higher than in some prior reports (12,13) . In our experience
(13), for example, we estimated that the incidence of serious
proarrhythmic effects after initiation of amiodarone appears
to be <1%
. Patients treated with amiodarone may have
bursts of tachycardia that appear to disappear with further
therapy .
Conclusions . The best approach to avoidance of serious
proarrhythmic effects is avoidance of high risk situations
where such effects become manifest
. Prior reports describe
patients at higher risk, namely, those with organic cardiac
disease with seriously impaired ventricular function . Several
additional findings from the report by Stanton et al . (8)
deserve emphasis
. For example, serious proarrhythmic
events may occur unassociated with significant lengthening
of either the QRS or the QT interval . The clinician must,
therefore, not be lulled into complacency when no significant
changes are found in these intervals after initiation of drug
therapy. Moreover, the finding that patients with nonsus-
tained ventricular tachycardia are at substantial risk for
development of proarrhythmic effects is equally important .
For patients with nonsustained ventricular tachycardia, in
particular, the clinician must carefully weigh risk versus the
projected benefits of initiating antiarrhythmic drug therapy .
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Stanton et al . (8) found the highest incidence of proar-
rhythmic events to be associated with use of the class IC
antiarrhythmic drugs . Our own experience (14), weighing the
evidence of efficacy versus adverse effects, leads us to
conclude that type IC drugs should not be used in the
management of patients with severe organic cardiac disease
and a history of sustained ventricular tachycardia or ventric-
ular fibrillation . To avoid infliction of harm, the clinician is
advised to execute caution in deciding whether antiarrhyth-
mic drugs should be used as well as knowledge of specific
drug effects for specific clinical situations .
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